Clinical trials: Lenvatinib
Hepatocellular Carcinoma, Lenvatinib
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE
- Trial name
- NCT05920863
- Testing
- TACE, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Renal Cell Carcinoma
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it eventually enables the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who have…
- Trial name
- NCT06129955
- Testing
- Pucotenlimab Combined With Lenvatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Neoplasm Malignant
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC)…
- Trial name
- NCT04976634
- Testing
- Pembrolizumab, Belzutifan, Lenvatinib
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 730 people
- Sponsor
- Merck Sharp & Dohme LLC
HCC - Hepatocellular Carcinoma
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable…
- Trial name
- NCT07801287
- Testing
- Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Renal Cell
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.
- Trial name
- NCT02454478
- Testing
- Lenvatinib, Everolimus
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Eisai Co., Ltd.
Unresectable Hepatocellular Carcinoma
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT05582278
- Testing
- D-TACE, HAIC, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wen Li